James M. Sweeney, Founder of the Home Infusion Therapy Industry, Has Died
Healthcare Pioneer, Humanitarian, and Author. The man the New York Times called "a pioneer in his field" and the Wall Street Journal described as "visionary" wanted most to be remembered for rescuing children from trafficking.
Born in
In 1979, Jim founded Caremark on a deceptively simple insight: patients receiving intravenous therapy didn't need to be in a hospital. They could be treated at home — more comfortably, less expensively, with their families. The industry didn't exist yet. Jim created it. Caremark was profitable within six months, grew to 75 centers nationwide within seven years, and was ultimately acquired by CVS. He is recognized today as the founder of the home infusion therapy industry. Over six decades, he went on to found fourteen companies that saved or extended the lives of millions.
In his final decade, Jim wrote Creative Insecurity: Lean into the Unknown and Unleash Your Inner Misfit (Post Hill Press/Simon & Schuster), co-authored with
"Lean into the unknown. Unleash your inner misfit."
—
About Dremana Productions
Dremana Productions is a full stack in-house marketing agency headquartered in Austin, Texas USA.
Press Contact:
Stephanie Adkins
773-616-7726
https://dremanaproductions.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/james-m-sweeney-founder-of-the-home-infusion-therapy-industry-has-died-302807399.html
SOURCE Dremana Productions
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insurance Agent Nick Hogan Explains What First-Time Homeowners Often Miss About Homeowners Insurance in HelloNation
- Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer
- GORGIE INTRODUCES BERRY BURST, BRINGING BOLD BERRY FLAVOR AND IT-GIRL STYLE TO MODERN ENERGY
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share